Search

Your search keyword '"Chi, Pei-Dong"' showing total 13 results
Start Over Author "Chi, Pei-Dong" Search Limiters Full Text
13 results on '"Chi, Pei-Dong"'

2. An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving Chemotherapy

Author

Wang, Yun, primary, Cai, Yan-yu, additional, Herold, Tobias, additional, Nie, Run-cong, additional, Zhang, Yu, additional, Gale, Robert Peter, additional, Metzeler, Klaus H., additional, Zeng, Yun, additional, Wang, Shun-qing, additional, Pan, Xue-yi, additional, Yang, Tong-hua, additional, Wu, Yuan-bin, additional, Zhang, Qing, additional, Wuxiao, Zhi-jun, additional, Du, Xin, additional, Liang, Zhi-wei, additional, Su, Yong-zhong, additional, Xu, Jing-bo, additional, Wang, Yong-qing, additional, Liu, Ze-lin, additional, Wu, Jian-wei, additional, Zhang, Xiong, additional, Wu, Bing-yi, additional, Xiao, Ruo-zhi, additional, Wang, San-bin, additional, Li, Jin-yuan, additional, Chi, Pei-dong, additional, Zhang, Qian-yi, additional, Chen, Si-liang, additional, Qin, Zhe-yuan, additional, Zhang, Xin-mei, additional, Zhong, Na, additional, Hiddemann, Wolfgang, additional, Liu, Qi-fa, additional, Zhang, Bei, additional, and Liang, Yang, additional

Published
2021
Full Text
View/download PDF

13. Evaluation of diagnostic efficacy of NRP-1/CD304 in hematological diseases.

Author

Liu YJ, Li XH, Song YL, Zhou YC, Cai RZ, and Chi PD

Subjects
Humans, Follow-Up Studies, Prognosis, Acute Disease, Leukemia, Myeloid, Acute diagnosis, Hematologic Diseases, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma metabolism, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Abstract

Background: Previous studies had explored the diagnostic or prognostic value of NRP-1/CD304 in blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and B-cell acute lymphoblastic leukemia (B-ALL), whereas the expression and application value of NRP-1/CD304 in other common hematological diseases have not been reported., Methods: Bone marrow samples from 297 newly diagnosed patients with various hematological diseases were collected to detect the expression of NRP-1/CD304 by flow cytometry (FCM). The diagnostic efficacy of NRP-1/ CD304-positive diseases was analyzed by receiver operating characteristic (ROC) curve, and the area under the ROC curve (AUC) was compared., Results: In the research cohort, the total positive rate of NRP-1/CD304 was 14.81% (44/297), mainly distributed in BPDCN (100%, 6/6), B-ALL (48.61%, 35/72), and AML (4.48%, 3/67), with statistically significant differences (p < 0.01). Other diseases, such as T-cell acute lymphoblastic leukemia (T-ALL), B-cell non-Hodgkin lymphoma (B-NHL), T/NK-cell lymphoma and plasma cell neoplasms, did not express NRP-1/CD304. The AUC of NRP-1/CD304 was 0.936 (95% CI 0.898-0.973), 0.723 (95% CI 0.646-0.801), and 0.435 (95% CI 0.435) in BPDCN, B-ALL and AML, respectively. Besides, CD304 was commonly expressed in B-ALL with BCR-ABL1 gene rearrangement (p = 0.000), and CD304 expression was positively correlated with CD34 co-expression (p = 0.009) and CD10 co-expression (p = 0.007)., Conclusions: NRP-1/CD304 is only expressed in BPDCN, B-ALL and AML, but not in other common hematological diseases. This indicates that NRP-1/CD304 has no obvious diagnostic and follow-up study value in hematological diseases other than BPDCN, B-ALL, and AML., (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results